AstraZeneca released updated phase three trial data for the Covid-19 vaccine after being questioned about the accuracy of its effectiveness in a preliminary report from its study in the US recently.
In the latest data released today, the vaccine showed 76% efficacy against symptomatic coronavirus disease and 100% efficacy against severe illness or the need for hospitalization.
The vaccine is 85% effective at preventing symptoms in volunteers aged 65 and older, the company said.
The figure is not much different from data released by the company in a statement via news release on Monday, which reported a 79%symptomatic efficacy rate.
According to AstraZeneca, the main analysis is in line with a previously released provisional analysis, and confirms that the vaccine is highly effective in adults, including those 65 years of age and older.
It hopes to submit the submission of the rule for emergency use authorization in the U.S. and prepare for the launch of millions of doses across America.
The company acted to release new data after the U.S. National Institute of Allergy and Infectious Diseases (NIAID) publicly criticized AstraZeneca for using outdated information in data published Monday.
